Enterprise Value

32.29M

Cash

74.32M

Avg Qtr Burn

N/A

Short % of Float

2.10%

Insider Ownership

5.56%

Institutional Own.

17.17%

Qtr Updated

03/31/23


Drug Pipeline

Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & IndicationStage & EventCatalyst Date
COM701 + Opdivo +/- BMS-986207 Details
Ovarian cancer, Cancer, Endometrial cancer

Phase 1/2

Data readout

COM701 + Opdivo Details
Solid tumor/s, Cancer

Phase 1b

Data readout

COM902 (TIGIT) Details
Cancer, Advanced malignancies

Phase 1

Data readout

COM701 (PVRIG) Details
Ovarian cancer, Colorectal cancer , Non-small cell lung carcinoma, Breast cancer, Endometrial cancer, Cancer

Phase 1

Data readout

COM701+COM902 +Pembrolizumab Details
Cancer, Platinum-resistant ovarian cancer

Phase 1

Data readout

COM701+COM902 +Pembrolizumab Details
Cancer, Colorectal cancer

Phase 1

Data readout